AIDS Healthcare Foundation (AHF) reported on Wednesday that the US will have 3m vaccine doses per day available by April in the fight against the COVID-19 variants.
In conjunction, the company's Ryan White HIV Clinics will offer its sites to administer the COVID-19 vaccines.
On Tuesday, AstraZeneca, Johnson & Johnson, Moderna, Novavax and Pfizer have reportedly testified at the US House of Representatives Energy and Commerce Subcommittee on Oversight and Investigations. Each company presented the scaled-up production numbers for the vaccines that have been approved by the US Food and Drug Administration (FDA).
AHF is the largest global AIDS organization and currently provides medical care and/or services to over 1.5m people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region as well as Eastern Europe.
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD
Egetis receives US notice of allowance for MCT8 deficiency composition patent
Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation